Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

NCT02187783

Conditions
Adenoma, Adnexal Diseases, Breast Diseases, +31 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Alaska Clinical Research Anchorage, Alaska, United States
  • Arizona Oncology Associates Dept. Of Onc. Phoenix, Arizona, United States
  • University of Arkansas/ Arkansas Cancer Research Center UA Medical Sciences Little Rock, Arkansas, United States
View all 61 locations
View Trial Details
Completed

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

NCT02046070

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hazard, Kentucky, United States
  • Boston, Massachusetts, United States
  • Rochester, Minnesota, United States
  • St Louis, Missouri, United States
View all 24 locations
View Trial Details
Completed

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Acrc/Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • Highland Oncology Group Fayetteville, Arkansas, United States
  • Comprehensive Blood And Cancer Center Bakersfield, California, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
View all 29 locations
View Trial Details
Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

NCT01282424

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +30 more
Locations
  • St. Jude Medical Center Fullerton, California, United States
  • Pacific Shores Medical Group Long Beach, California, United States
  • UCLA Los Angeles, California, United States
  • Central Coast Medical Oncology Santa Maria, California, United States
View all 41 locations
View Trial Details
Completed

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00104858

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +25 more
Locations
  • Mayo Clinic Rochester, Minnesota, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Rigshospitalet University Hospital Copenhagen, Denmark
View Trial Details
Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

NCT02811822

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Vejle Hospital Vejle, Denmark
  • Medizinische Klinik/Abt. Innere Medizin V Heidelberg, Germany
  • Cork University Hospital, Wilton Cork, Ireland
  • Beaumont Hospital Dublin, Ireland
View Trial Details

Related conditions